I'm LongbridgeAI, I can summarize articles.R&G Pharma released its 2024 annual report, with operating revenue of 744 million yuan, a year-on-year increase of 3.14%. The net profit attributable to the parent company was 140 million yuan, a year-on-year decrease of 13.73%. The net profit after deducting non-recurring gains and losses was 114 million yuan, a year-on-year decrease of 11.36%. The basic earnings per share were 1.47 yuan, and it plans to distribute a cash dividend of 1.60 yuan (including tax) for every 10 shares to all shareholders
According to the Zhitong Finance APP, R&G Pharma (301333.SZ) released its annual report for 2024, reporting an operating income of 744 million yuan, a year-on-year increase of 3.14%. The net profit attributable to shareholders of the listed company was 140 million yuan, a year-on-year decrease of 13.73%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 114 million yuan, a year-on-year decrease of 11.36%. The basic earnings per share were 1.47 yuan. In addition, it plans to distribute a cash dividend of 1.60 yuan (including tax) for every 10 shares to all shareholders